Citations

Clear

5 citation(s) found for "Sinai, Anat".

Hyperaldosteronism Remission after Extended Aldosterone Synthase Inhibition
Brown, Morris Jonathan , Turcu, Adina F. , Sam, Ramin , Kirschner, Lawrence S. , Hamidi, Oksana , Eren, Aysegul, Ben-Shlomo, Anat , Huang, Wenyu , Bancos, Irina , Hamrahian, Amir Hekmat , Freeman, Mason W.

Mayo Clinic

New England Journal of Medicine | November 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1056/nejmc2611265 | PMID 43001732 Get It

Consensus on biomarker utility for ACTH-dependent Cushing syndrome: a Pituitary Society Modified Delphi Panel
Fleseriu, Maria , Biller, Beverly M. K. , Reincke, Martín , Мелмед, Шломо , Group, the Pituitary Society International Cushing Syndrome Delphi Panel Consensus, Akirov, Amit , Araki, Takako, Auchus, Richard, Ben-Shlomo, Anat , Bertherat, Jérôme, Biermasz, Nienke R, Castinetti, Frédéric, Ceccato, Filippo, Christ-Crain, Mirjam, Feelders, Richard A. , Findling, James W. , Gadelha, Monica, Geer, Eliza B, Giustina, Andrea, Grossman, Ashley, Gurnell, Mark, Hanzu, Felicia, Hinojosa-Amaya, Jose M, Isand, Kristina , Isidori, Andrea M, Kadioğlu, Pinar, Karavitaki, Niki, McCormack, A I, Nieman, Lynnette, Nowak, Elisabeth, Pivonello, Rosario, Salvatori, Roberto , Stewart, Paul M., Tabarin, Antoine, Takahashi, Yutaka, Theodoropoulou, Marily , Valassi, Elena, Varlamov, Elena V , Walia, Rama, Wass, John, Cheung, Cassandra, Priven, Mariel , Brown, Marielle, Biller, Beverly M K , Bancos, Irina , Fukuoka, Hidenori , Reincke, Martin , Newell-Price, John , Melmed, Shlomo , Bancos, Irina , Newell‐Price, John , Bertherat, Jérôme , Bidlingmaier, Martin , Biermasz, Nienke Ruurdje , Castinetti, Frédéric , Ceccato, Filippo , Christ‐Crain, Mirjam , Gadelha, Mônica R. , Geer, Eliza B. , Glezer, Andréa , Giustina, Andrea , Greenman, Yona , Grossman, Ashley, Gurnell, Mark , Hanzu, Felicia Alexandra , Hinojosa‐Amaya, José Miguel , Isidori, Andrea M. , Kadıoğlu, Pınar , Karavitaki, Niki , Langlois, Fabienne , Nieman, Lynnette K. , Nowak, Elisabeth , Pereira, Alberto M. , Petersenn, Stephan , Pivonello, Rosario , Tabarin, Antoine , Valassi, Elena , Vila, Greisa , Brown, Marielle, Fleseriu, Maria

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag279 | PMID 42460773 Get It

Abstract Context Biochemical test results are central to clinical decision-making for the diagnosis and management of Cushing syndrome (CS). With emerging research and increasing availability of different tests, updated consensus on the utility of these biomarkers is warranted. Objective To establish an updated consensus on the role of biomarkers in the diagnosis and monitoring of adrenocorticotropic hormone-dependent CS, address novel therapeutic approaches, and identify areas for future research. Design A modified 2-round Delphi panel was conducted. Consensus was defined as ≥70% agreement/disagreement for Likert-scale statements or ≥70% selection of the same option for single-choice questions. Setting Participants represented a range of international expertise. Participants Forty-one participants took part in the Delphi panel, with no attrition between rounds (one nonclinician was not required to complete the second round). An 8-member Steering Committee guided statement development. Results Of statements designed to reach consensus, 45% (14/31) and 44% (11/25) statements reached consensus in Rounds 1 and 2, respectively. Notably, most panelists reported the use of late-night salivary cortisol for diagnosis of mild CS and for monitoring following pituitary surgery or medical or radiation therapy. Most panelists responded that block-and-replace therapies can be considered in patients with cyclical or severe CS, and consensus was reached that restoration of circadian rhythm is a treatment goal for patients with CS. Conclusion Areas of alignment among experts on the diagnosis and monitoring of CS are presented. The findings from this study are intended to support clinicians in their clinical decision-making and highlight priority areas for future research.
ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states
Barredo, Bianca, Patnaik, Mrinal M. , Li, Peng , Vagher, Jennie , Pelletier, Sarah, Oster, Howard S. , Goldschmidt, Noa, Sinai, Anat, Basood, May, Trottier, Amy M. , Andreossi, Gloria, Heinrich, Michael , Brewer, Diana, Shoger, Kyle, Fonseca, Gustavo , Fiala, Elise , Birsoy-Ceyhan, Ozge, Offit, Kenneth , McGuinness, Molly , Drazer, Michael W. , Satty, Alexandra , Vlachos, Adrianna , Churpek, Jane , Drazer, Michael , Banaszak, Lauren Gabriele , Włodarski, Marcin W. , Lewis, Sara, Ferrer, Alejandro , Fox, Lucy C. , Osman, Afaf E.G. , DiNardo, Courtney D. , Stewart, Brittany, Carraway, Hetty E. , Mittelman, Moshe , Santini, Valeria , Druker, Brian J , Smith-Simmer, Kelcy J. , Kemel, Yelena , Mandelker, Diana L. , Marderstein, Andrew R. , Stadler, Zsofia , Cantor, Alan B , Bledsoe, Jacob R. , Homan, Claire C. , Brown, Anna

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1440-1440

10.1182/blood-2025-1440 Get It

Abstract Introduction Heterozygous germline pathogenic variants (PVs) in the 5' untranslated region of ANKRD26 cause inherited thrombocytopenia and predisposition to hematologic malignancy (HM). The estimated lifetime HM risk is ~10% based on families ascertained from an inherited thrombocytopenia cohort. However, the malignancy spectrum, molecular features, precursor states, and overall clinical outcomes remain poorly defined. Methods We established an international, multicenter cohort of individuals with ANKRD26-related thrombocytopenia diagnosed after undergoing genetic evaluation due to a personal and/or family history of thrombocytopenia and/or HM. Clinical, pathologic, and molecular data were collected for 27 individuals with germline ANKRD26 PVs from 21 unrelated families treated at 11 institutions across 5 countries. Statistical analyses were performed using R (v4.4.2). Results Patients were predominantly male (18/27) and white (25/27). Thrombocytopenia was typically identified in childhood (median age 10 years, range 0-48) with a genetic diagnosis made later (median age 53 years, range 2-80). The mean (+/- SD) pre-malignancy platelet count was 45 +/- 24 K/uL (range 5-87). ANKRD26 PVs observed in each family included: c.-126T>C (n=9), c.-128G>A (n=3), c.-134G>A (n=3), c.-116C>T (n=3), c.-118C>T (n=2), and c.-118C>A (n=1). Thirteen HMs were diagnosed in 11 of 27 (41%) patients, including myelodysplastic neoplasm/syndrome (MDS, n=5), acute myeloid leukemia (AML, n=3), chronic myeloid leukemia (CML, n=2), MDS/myeloproliferative neoplasm (MPN) overlap (n=2), and Langerhans cell histiocytosis (n=1). The median age at first HM diagnosis was 63 years (range 49-80). Recurrent somatic features in myeloid malignancies included complex karyotype (4/11, 36%) and TP53 mutations (5/10, 50%). Of the 3 patients with AML, 1 achieved a partial remission (PR) with venetoclax combined with cladribine, idarubicin, and cytarabine but relapsed, 1 achieved a PR with azacitidine but relapsed <100 days after haploidentical allogeneic stem cell transplantation (alloSCT), and 1 had primary refractory disease. Among 5 patients with MDS, 1 was refractory to decitabine, 1 underwent alloSCT but relapsed 2 years post-transplant, 1 remains in remission post-alloSCT with 1 year of follow-up, 1 is undergoing alloSCT evaluation, and 1 was lost to follow-up. Both patients with CML achieved durable major molecular remissions with imatinib. To better estimate HM risk, we assumed 100% penetrance of thrombocytopenia for ANKRD26 PV carriers and included family members with chronic thrombocytopenia who had not had germline genetic testing. In this expanded series (n=62), 16 individuals developed a HM (26%). Additional diagnoses included MDS with progression to AML (n=1), AML (n=1), CML (n=1), and leukemia of unknown type (n=2). Cumulative incidence of HM was 0% by age 40 years, 17% by age 60 years, and 60% by age 80 years. Somatic sequencing of peripheral blood was performed in 5 HM-unaffected ANKRD26 PV carriers. One individual was found to have clonal hematopoiesis driven by TET2 (c.1648C>T, p.Arg550*) with a variant allele frequency (VAF) of 9% at age 55. Bone marrow biopsy showed mild megakaryocytic atypia and 4% blasts without overt evidence of malignancy. To assess the prevalence of ANKRD26-related HM, we assessed the frequency of ANKRD26 PVs in 2 large MDS/AML cohorts. In the ARUP database (9662 AML, 6397 MDS), 2 individuals (0.01%) had an ANKRD26 PV with a VAF consistent with germline origin. In the MSK-IMPACT Heme Germline MDS/AML cohort (n = 284), no ANKRD26 P/LP variants were identified. Conclusions Germline ANKRD26 PVs underlie <1% of MDS/AML diagnoses but may represent a high-risk subtype characterized by complex karyotype, TP53 mutations, and high risk of relapse. Among our series, the incidence of HM was low early in life but increased substantially with age, reaching 60% by 80 years. This exceeds prior estimates, which were derived from individuals ascertained from thrombocytopenia-based registries. Together, our findings suggest that ANKRD26-associated HM may represent a high-risk clinical entity, and that age and family history should inform surveillance strategies. More studies are needed to define genetic and environmental modifiers of HM risk as well as precursor states to enable early detection and disease interception.
OR16-08 Baxdrostat in Patients with Primary Aldosteronism: Results from the SPARK Phase 2 Trial
Ben-Shlomo, Anat , Huang, Wenyu , Sam, Ramin , Lihn, Aina Sætre, Perl, Shira, Tuyishimire, Bonifride, Bancos, Irina , Hamidi, Oksana , Hamrahian, Amir Hekmat , Kirschner, Lawrence S. , Turcu, Adina F. , Mallappa, Ashwini , Brown, Morris Jonathan

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.798 Get It

Abstract Disclosure: I. Bancos: AstraZeneca. A. Ben-Shlomo: AstraZeneca. O. Hamidi: Recordati Rare Diseases, Neurocrine Biosciences, Corcept Therapeutics, Crinetics, Camurus, Xeris. A. Hamrahian: AstraZeneca. W. Huang: None. L.S. Kirschner: Corcept Therapeutics, AstraZeneca, Crinetics, Sparrow Pharma, Spruce Biosciences. R. Sam: AstraZeneca. A.F. Turcu: AstraZeneca. A. Lihn: AstraZeneca. A. Mallappa: AstraZeneca. S. Perl: AstraZeneca. B. Tuyishimire: AstraZeneca. M.J. Brown: GlaxoSmithKline, Pfizer, Inc., Bristol-Myers Squibb, AstraZeneca. Introduction: Mineralocorticoid receptor antagonist (MRA) treatment for primary aldosteronism (PA) has limited efficacy in some patients. Highly selective, competitive aldosterone synthase inhibitors (ASIs) offer an alternative therapeutic approach. SPARK (NCT04605549) was a Phase 2, open-label, multicenter trial of the ASI baxdrostat in patients with PA. Methods: Eligibility entailed: aged ≥18 years; diagnosis of PA; willingness to discontinue MRA up to 4 weeks before baxdrostat initiation; and systolic blood pressure (SBP) rise ≥20 mmHg or SBP ≥160 mmHg after discontinuation of MRA, or SBP ≥150 mmHg for patients with newly diagnosed PA who had not taken MRAs in the past 12 weeks. Patients entered a 12-week treatment period (Part 1) of once daily baxdrostat 2 mg, up-titrated to 4 mg or 8 mg at week (W) 4 or W8, respectively, if there was no significant risk of hypotension. Baxdrostat could be down-titrated to 2 mg or continued at 4 mg as needed. After W12, patients could continue baxdrostat up to W72 (Part 2) with doses at investigators’ discretion. Primary endpoints were safety, tolerability and change from baseline in mean seated SBP at W12. Results: Fifteen patients enrolled and completed Part 1; 14 patients continued to Part 2. Median (range) age was 54 (32, 75) years, 67% of patients were male, 47% were White, and median (range) body mass index was 32.0 (24.4, 41.4) kg/m2. At baseline, plasma renin activity (PRA) was <1 ng/mL/h in 12/15 (80%) patients, and 8/15 (53%) patients had hypokalemia (serum potassium <3.5 mmol/L). Mean (range) baseline SBP was 151.5 (130, 174) mmHg; diastolic BP (DBP) was 90.3 (74, 103) mmHg. At W12, mean (range) SBP change from baseline was –29.5 (–47, –12), –24.4 (–31, –17), and –23.9 (–47, –8) mmHg for patients on baxdrostat 2 mg (n=2), 4 mg (n=5), and 8 mg (n=7), respectively; DBP change was –8.0 (–14, –2), –10.4 (–20, 0), and –11.6 (–25, 7) mmHg, respectively. Overall, 11/15 (73%) patients achieved BP <140/90 mmHg and 6/15 (40%) achieved BP <130/80 mmHg at W12; reduced BP persisted in Part 2. No deaths were reported. Nine out of 15 (60%) patients had a treatment-emergent adverse event (TEAE) during W4–W12 of Part 1 (all mild/moderate), including 1/15 (7%) patient with hyperkalemia; no serious TEAEs were reported. In Part 2, 14/14 (100%) patients had a TEAE (most mild/moderate), including 5/14 (36%) patients with hyperkalemia; one serious TEAE of hyperkalemia was reported. Mean (standard deviation, SD) serum potassium levels increased from 3.9 (0.6) mEq/L at baseline to 4.7 (0.5) mEq/L at W12. Mean (SD) 24-h urine aldosterone excretion at baseline and W12 were 30.3 (17.5) and 3.2 (2.7) µg/day, respectively. At W12, 7/15 (47%) patients had achieved unsuppressed PRA (≥1.0 ng/mL/h). Conclusions: Baxdrostat, an ASI, was well tolerated and led to reduced BP and unsuppressed renin in patients with PA. Inhibiting aldosterone synthase may be an alternative to MRAs for treating PA. Presentation: Sunday, July 13, 2025
Phase 2a Study of Baxdrostat in Primary Aldosteronism
Freeman, Mason W. , Ben-Shlomo, Anat , Huang, Wenyu , Kirschner, Lawrence S. , Sam, Ramin , Tuyishimire, Bonifride, Lihn, Aina Sætre, Perl, Shira, Brown, Morris Jonathan , Turcu, Adina F. , Bancos, Irina , Hamidi, Oksana , Hamrahian, Amir Hekmat , Mallappa, Ashwini

Mayo Clinic

New England Journal of Medicine | July 13, 2025 | Volume: 393 | Issue: 5 | Pages: 515-518

10.1056/nejmc2508629 | PMID 40658651 Get It